Philadelphia, PANCT07167446Now EnrollingIRB Ready

Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients Clinical Trial in Philadelphia, PA

Access cutting-edge oxaliplatin induced peripheral neuropathy in cancer patients treatment through this early phase 1 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Fox Chase Cancer Center

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access oxaliplatin induced peripheral neuropathy in cancer patients specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related oxaliplatin induced peripheral neuropathy in cancer patients treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this oxaliplatin induced peripheral neuropathy in cancer patients clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients Study in Philadelphia

This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.

Sponsor: Fox Chase Cancer Center

Who Can Participate

Inclusion Criteria

Patients with metastatic, locally advanced unresectable colorectal cancer patients planned to receive Ox based chemotherapy in metastatic setting (at least 3 months planned).
Subjects are allowed to have one cycle of Ox based chemotherapy before enrollment.
ECOG PS 0-2
No prior platinum exposure
No evidence of ongoing neuropathy of any grade at the time of enrollment
Patients must have marrow and organ function appropriate for systemic therapy, as per physician's discretion, but liver function should meet criteria below:
Total Bilirubin: less than and/or equal to 1.5 X ULN
AST(SGOT)/ALT(SGPT): less than and/or equal to 3 X ULN (5 X ULN in patients with liver metastases
Ability to understand and willingness to sign a written informed consent and HIPAA consent document.

Exclusion Criteria

Family history of genetic/familial neuropathy and personal history of ongoing neuropathy (any grade) or nervous system disease with the potential to affect cognition, Parkinson's disease, or multiple sclerosis.
Routine use of recreational marijuana products (defined as \> 4 times per month) or illicit drug use per self-reported history within the last 90 days. If using medical cannabis products, it should be stopped at least 1 week prior to inclusion.
Known underlying liver disease (Child-Pugh B or C) or baseline elevation of total bilirubin greater than and/or equal to 1.5 x upper limit of normal based on screening laboratory values.
1Untreated brain metastases (can increase seizure risk), or treated brain metastases on anti-seizure medications.
Patients being treated with anti-seizure or anti-psychotic medications. Patients with a prior history of anti-seizure medication use, who have been off treatment for more than 3 months, are eligible. Use of Selective Serotonin Reuptake Inhibitors (SSRIs) is permitted.
Concomitant treatment with strong inducers of CYP3A4 and/or strong inducers of CYP2C19.
Underlying history of epilepsy/recurrent seizure disorder or unexplained seizure within past 6 months.
Patients with current or lifetime diagnosis of schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022)
Recent history or clinical concern for major depression with suicidal ideation as determined by investigator assessment at baseline
Currently taking medications known to be contraindicated with Epidiolex -FDA-approved CBD (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate).
Women who are pregnant or breastfeeding, and individuals of any sex who are capable of reproduction and unwilling to use an effective form of birth control (e.g., condoms, diaphragm, birth control pills, or IUD).
Patients may not be receiving any other investigational agents.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT07167446) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients Treatment Options in Philadelphia, PA

If you're searching for oxaliplatin induced peripheral neuropathy in cancer patients treatment options in Philadelphia, PA, this clinical trial (NCT07167446) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced oxaliplatin induced peripheral neuropathy in cancer patients specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all oxaliplatin induced peripheral neuropathy in cancer patients clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Philadelphia, PA

See all pulmonary embolism clinical trials recruiting in Philadelphia — not just this study.

Browse Pulmonary Embolism Trials in Philadelphia →

Browse More Trials by Condition

Pulmonary Embolism TrialsNeuropathy TrialsRheumatoid Arthritis TrialsUlcerative Colitis TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA